Maternal disease activity and serological activity as predictors of adverse pregnancy outcomes in women with systemic lupus erythematosus: a retrospective chart review

Arch Gynecol Obstet. 2022 May;305(5):1177-1183. doi: 10.1007/s00404-021-06148-x. Epub 2021 Sep 17.

Abstract

Purpose: To evaluate the association between disease activity, serological activity, and adverse pregnancy outcomes (APOs) in women with systemic lupus erythematosus (SLE) and determine the cut-off values of complements to predict APOs in live birth cases.

Methods: This retrospective chart review included pregnant women with SLE who had singleton live births after 22 weeks between 2006 and 2020. First trimester maternal disease activity was assessed for SLE onset during pregnancy, antiphospholipid syndrome, SLE pregnancy disease activity index (SLEPDAI), disease flare-ups, lupus nephritis, pancytopenia, and daily prednisolone dosage. Serological activity was assessed for autoantibodies and complements. APOs included preterm birth (PTB), low birth weight infants, small-for-gestational age infants, preterm premature rupture of membranes, and preeclampsia (PE). Chi-square and Fisher's exact tests were used to compare categorical variables; a receiver-operating characteristic analysis was performed to calculate the cut-off values of complements to predict APOs.

Results: Fifty-two participants met the inclusion criteria. The incidence of PTB and PE was associated with a high SLEPDAI (p < 0.001, p = 0.001), disease flare-ups (p = 0.007, p < 0.001), lupus nephritis (p = 0.020, p = 0.012), anti-dsDNA antibodies (p = 0.047, p = 0.016), anti-SSA antibodies (p = 0.003, p = 0.004), low CH 50 (p < 0.001, p < 0.001), low C3 (p < 0.001, p < 0.001), and low C4 (p < 0.001, p = 0.001), respectively. The cut-off values of C4 to predict PTB and PE were 13.0 mg/dL (higher than the normal lowest limit).

Conclusion: High maternal disease activity and high serological activity in the first trimester in women with SLE are significantly associated with APOs. Proper disease control and close management for hypocomplementemia are required for better perinatal outcomes.

Keywords: Adverse pregnancy outcomes; Autoantibody; Disease activity; Hypocomplementemia; Systemic lupus erythematosus.

MeSH terms

  • Antibodies, Antinuclear
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / drug therapy
  • Lupus Erythematosus, Systemic* / epidemiology
  • Lupus Nephritis* / complications
  • Male
  • Pre-Eclampsia* / epidemiology
  • Pregnancy
  • Pregnancy Complications* / epidemiology
  • Pregnancy Outcome / epidemiology
  • Premature Birth* / epidemiology
  • Retrospective Studies
  • Symptom Flare Up

Substances

  • Antibodies, Antinuclear
  • anti-dsDNA autoantibody